Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Scottish medicines consortium approves CAR T-cell therapy for blood cancer - 7 days ago Arcellx to present positive data on multiple myeloma treatments - 12 days ago Celltrion unveils promising dose escalation results for subcutaneous infliximab - about 1 month ago Poolbeg’s cytokine release syndrome drug shows potential - 10 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 13 days ago STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer - 11 months ago STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation - about 1 year ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - about 1 month ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago FDA Greenlights First Engineered Cell Therapy for a Solid Tumor - 4 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 4 months ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - 12 months ago
4	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - about 2 months ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 3 months ago FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease - 4 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 4 months ago FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 8 months ago Celltrion USA Submits Biologics License Application for CT-P39, a Biosimilar to Xolair - 8 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 9 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 9 months ago FDA Grants Accelerated Approval to Lifileucel For Treatment of Advanced Melanoma - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 11 months ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - 4 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - 4 months ago STAT+: In the U.S., scientists see barriers to the development of CAR-T cell therapies. In Spain, a hospital brews its own - 11 months ago
9	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 4 months ago Is a better CAR-T cell therapy option on the horizon? - 4 months ago
10	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer - 5 months ago

Journalists covering Celltrion